From pixels to precision: Artificial intelligence in diabetic eye disease screening and management

Abstract

Artificial intelligence (AI) is transforming the landscape of diabetic care, bridging the gap between early detection and personalized disease management. In ophthalmology, AI-driven algorithms have demonstrated remarkable accuracy in identifying diabetic retinopathy and diabetic macular edema from retinal fundus and optical coherence tomography images, rivaling expert graders while offering scalable, cost-effective solutions for population-level screening. Beyond image analysis, AI is emerging as a powerful decision-support tool that integrates systemic data, glycemic control metrics, and imaging biomarkers to predict disease progression and treatment response. This narrative opinion review explores how AI can reshape diabetic patient management through predictive analytics, remote monitoring, and automated triage systems, enabling timely referrals and individualized follow-up. We also discuss the ethical, regulatory, and practical barriers to clinical translation, emphasizing the need for explainable algorithms, real-world validation, and interdisciplinary collaboration. By shifting from reactive treatment to proactive prediction, AI promises to redefine the continuum of diabetic eye care – from screening to precision-guided management – ultimately reducing blindness and healthcare burden worldwide.

Keywords: Artificial intelligence; Ophthalmic imaging; Diabetic retinopathy; Deep learning; Macular edema

Core Tip: Artificial intelligence (AI) is transforming diabetic eye care through automated detection, risk assessment, and precision management. Deep learning algorithms utilized in fundus photography and optical coherence tomography imaging now equal or surpass experienced graders in the detection of diabetic retinopathy and macular edema. In addition to screening, AI incorporates multimodal data – such as systemic parameters, imaging biomarkers, and treatment histories – to predict disease progression and therapeutic outcomes. This review articulates contemporary clinical uses, technical underpinnings, and translational obstacles, while delineating potential trajectories for the development of explainable, morally robust, and globally scalable AI systems that can revolutionize the management of diabetic eye disease.